Background: Precision oncology requires integration of heterogeneous molecular and pathology data, yet many fusion models offer limited biologically grounded interpretability and struggle with missing modalities. Methods: We present Hierarchical Interpretable Tensor Fusion (HIT-Fuse), integrating six modalities: somatic copy number variation, DNA methylation, RNA sequencing, microRNA expression, RPPA protein abundance, and vision transformer-derived pathomics across four TCGA cohorts (glioma, lung adenocarcinoma, breast, and kidney cancer). Modality-specific autoencoders compress high-dimensional inputs, followed by two-stage CP tensor decomposition. Missing latent modalities are reconstructed using clinical covariates and observed omics to expand cohorts and retrain downstream models. A mathematical traceback mechanism enables global and local xAI attributions. Results: HIT-Fuse identifies distinct latent subgroups with significant survival stratification in glioma, breast, and kidney cohorts, both with complete and reconstructed modalities. Cohort expansion yields cohort-specific gains, including a 56.4% relative increase in weighted F1 for glioma. Biological validation against DepMap CRISPR screens, miRTarBase and RPPA annotations supports decoded drivers across all four cohorts. Essential gene rates range from 6.2% in glioma to 7.6% in lung cancer; example drivers include ANAPC11, SNRPD1, PLK1 and RPL14. Of decoded miRNAs, 71-92% have miRTarBase regulatory support, while 77-84% of selected genes are covered in DepMap. Conclusions: HIT-Fuse combines hierarchical tensor fusion, missing-modality reconstruction and traceable attributions to support interpretable multi-omics and digital pathology-based cancer prognosis across heterogeneous cohorts.
翻译:暂无翻译